Description

Denocad 60 mg contains Denosumab, a fully human monoclonal antibody that targets the RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) protein responsible for bone breakdown. By blocking RANKL, Denosumab helps prevent bone loss and improves bone density.

🔬 Mechanism of Action

Denosumab binds to the RANKL protein and prevents it from activating the RANK receptor on osteoclasts (cells responsible for bone resorption). As a result, it:

• Reduces bone breakdown
• Increases bone mineral density
• Strengthens bones and lowers fracture risk

💊 Indications

Denocad 60 mg is indicated for:

• Osteoporosis in postmenopausal women at high risk of fractures
• Osteoporosis in men at increased fracture risk
• Bone loss associated with hormone therapy in breast or prostate cancer patients

📌 Key Features of Denocad 60 mg

• Strength: 60 mg
• Dosage Form: Subcutaneous injection
• Therapeutic Class: RANKL Inhibitor / Monoclonal Antibody
• Administration: Given as a subcutaneous injection once every 6 months under medical supervision
• Monitoring: Calcium levels and bone health monitoring recommended

⚕️ Benefits of Denosumab

• Significantly increases bone mineral density
• Reduces risk of vertebral, hip, and non-vertebral fractures
• Long-acting therapy with twice-yearly dosing
• Effective for osteoporosis and cancer therapy–related bone loss

⚠️ Precautions

• Risk of hypocalcemia; calcium and vitamin D supplementation may be recommended
• Rare risk of osteonecrosis of the jaw (ONJ)
• Possible infections or skin reactions
• Regular monitoring of calcium levels is required
• Use under physician supervision

Denocad 60 mg (Denosumab Injection) is an effective bone-protective therapy designed to strengthen bones, reduce fracture risk, and improve bone health in patients with osteoporosis or cancer treatment–related bone loss.